Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness (NEO-AWARE)

5 novembre 2026 mis à jour par: Karlijn Van Damme, University Hospital, Antwerp

Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness in a Post-Implementation Prospective Study With Pre-Implementation Historical Comparison

This study aims to evaluate the Intellicens software, an artificial intelligence (AI)-based early warning system designed to help doctors and nurses detect serious complications in premature babies at an early stage. These complications include bloodstream infections (sepsis) and necrotizing enterocolitis (NEC), a serious condition affecting the intestines.

The study will involve babies born before 32 weeks of pregnancy who are admitted to the Neonatal Intensive Care Unit (NICU). The Intellicens Neo model analyses routinely collected medical data, such as heart rate, to identify patterns that may indicate an increased risk of sepsis or NEC and generate an early warning for healthcare professionals. The treating doctor remains responsible for deciding whether further examinations or treatment are needed.

The software has previously been tested using data from babies who had already been discharged from hospital, with promising results. This study will evaluate how well the software performs in real-life clinical practice during the hospital stay.

Aperçu de l'étude

Statut

Pas encore de recrutement

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

500

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Antwerp
      • Edegem, Antwerp, Belgique, 2650
        • Antwerp University Hospital
        • Contact:
      • Amsterdam, Pays-Bas
        • Amsterdam UMC
      • Rotterdam, Pays-Bas
        • Erasmus MC Rotterdam

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Neonates born below a gestational age of 32 weeks
  • Admitted to the NICU
  • Written informed consent

Exclusion Criteria:

  • Severe congenital malformations
  • Admission for palliative care

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intellicens Neo implementation group

Preterm infants born at less than 32 weeks of gestational age admitted to participating neonatal intensive care units (NICUs) after implementation of Intellicens Neo. The software generates visual alerts for potential late-onset sepsis (LOS) and necrotizing enterocolitis (NEC). Alerts are visible to the clinical care team, while clinical assessment and treatment decisions remain at the discretion of the treating clinicians. Study outcomes will be compared with a historical pre-implementation dataset.

Intellicens Neo is investigational medical device software designed to support early warning of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm infants admitted to the neonatal intensive care unit (NICU). The software calculates a NeoSep Index every 30 minutes and generates visual alerts when predefined alert criteria are met. The alerts are made visible to the clinical care team to support awareness of potential LOS or NEC. Clinical assessment and treatment decisions remain at the discretion of the treating clinicians. The intervention is evaluated in a prospective, multicenter, post-implementation clinical investigation, with outcomes compared with a pre-implementation historical dataset.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The time between the last Intellicens Neo visual alert preceding LOS/NEC diagnosis and the timepoint of administration of IV antibiotics.
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the last Intellicens Neo visual alert preceding the diagnosis of late-onset sepsis (LOS) or necrotizing enterocolitis (NEC) and the administration of intravenous antibiotics for that episode. This outcome evaluates whether the availability of Intellicens Neo alerts is associated with earlier initiation of antibiotic treatment in preterm infants with LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 3 hours.
Délai: Within 3 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

Primary outcome in the substudy, analysis done only in the first 150 patients enrolled. The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 3 hours after the visual alert is generated.

Within 3 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
The time between the last Intellicens Neo visual alert preceding LOS/NEC diagnosis and the timepoint of LOS/NEC diagnosis.
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the start of the last Intellicens Neo visual alert preceding a LOS/NEC episode and the time of LOS/NEC diagnosis. The time of diagnosis is defined as the time of the blood culture order in the patient's electronic health record.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Incidence of severe LOS/NEC.
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Occurrence of severe late-onset sepsis (LOS) or necrotizing enterocolitis (NEC) episodes in the study population. The number of severe LOS/NEC episodes will be compared between the prospective cohort and the pre-implementation historical cohort.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Length of NICU stay
Délai: From birth until NICU discharge, with an estimated maximum of 25 weeks.

Total duration of the patient's stay in the neonatal intensive care unit (NICU), measured from NICU admission to NICU discharge.

From birth until NICU discharge, with an estimated maximum of 25 weeks.
Total duration of intravenous antibiotic therapy
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Total number of days of intravenous antibiotic treatment during the patient's NICU stay.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Number of suspected LOS episodes
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Total number of suspected late-onset sepsis (LOS) episodes recorded during the patient's NICU stay.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
LOS/NEC-related mortality
Délai: Within 7 days after LOS/NEC diagnosis.

Occurrence of mortality related to late-onset sepsis (LOS) or necrotizing enterocolitis (NEC), defined as mortality occurring within 7 days after LOS/NEC diagnosis.

Within 7 days after LOS/NEC diagnosis.
Performance of the Intellicens Neo software device ML model on the prospective dataset: sensitivity
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the sensitivity/recall of the ML model: the percentage of detected LOS/NEC episodes by the Intellicens Neo software device

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: specificity
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the specificity of the ML model

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: precision
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the precision of the ML model: the amount of (false positive) visual alerts generated by the Intellicens Neo software device represented by the total number of 24-hour time-windows in which a false positive visual alert occurred

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: visual alert rate
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the visual alert rate of the ML model: total number of alert days per patient per week.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Number needed to predict
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Number of patients who need to be examined to detect one patient with the relevant disease (LOS or NEC).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Time from LOS/NEC diagnosis to intravenous antibiotic treatment
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the time of LOS/NEC diagnosis, defined as the time of the blood culture order in the patient's electronic health record, and the time of intravenous antibiotic treatment, defined as the time of the order of the first dose of intravenous antibiotics in the patient's electronic health record.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 1 hour
Délai: Within 1 hour after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 1 hour after the visual alert is generated.

Within 1 hour after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 6 hours
Délai: Within 6 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 6 hours after the visual alert is generated.

Within 6 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of all Intellicens Neo visual alerts that are acknowledged by the clinical care team, irrespective of the time taken to acknowledge them.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to clinical action
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by a clinical action related to suspected LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to laboratory evaluation for LOS/NEC suspicion
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by laboratory evaluation for suspected late-onset sepsis (LOS) or necrotizing enterocolitis (NEC).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to initiation of intravenous antibiotic treatment
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by initiation of intravenous antibiotic treatment for suspected LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts dismissed by the clinical care team
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are dismissed by the clinical care team.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Time from Intellicens Neo visual alert to the first related clinical action
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between an Intellicens Neo visual alert and the first clinical action related to that alert.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Association between time of day and time to visual alert acknowledgement
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Evaluation of the effect of time of day on the time to acknowledgement of Intellicens Neo visual alerts. Time periods are defined as day shift (08:30-17:00), evening shift (17:00-23:00), and night shift (23:00-08:30).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Association between Intellicens Neo alert burden and time to visual alert acknowledgement
Délai: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Evaluation of the effect of alert burden on the time to acknowledgement of Intellicens Neo visual alerts. Alert burden is defined as the presence of at least 2 visual alerts in the same patient during the preceding week.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

9 novembre 2026

Achèvement primaire (Estimé)

31 mars 2028

Achèvement de l'étude (Estimé)

31 mars 2028

Dates d'inscription aux études

Première soumission

31 octobre 2026

Première soumission répondant aux critères de contrôle qualité

5 novembre 2026

Première publication (Réel)

12 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner